9,975 Shares in MEDNAX Inc (NYSE:MD) Bought by Point72 Hong Kong Ltd
Point72 Hong Kong Ltd bought a new stake in MEDNAX Inc (NYSE:MD) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 9,975 shares of the company’s stock, valued at approximately $277,000.
Other institutional investors have also recently modified their holdings of the company. Oxford Asset Management LLP purchased a new position in shares of MEDNAX in the 4th quarter valued at $1,064,000. Millennium Management LLC increased its holdings in MEDNAX by 381.5% in the 3rd quarter. Millennium Management LLC now owns 340,081 shares of the company’s stock valued at $7,692,000 after purchasing an additional 269,457 shares in the last quarter. BBVA USA Bancshares Inc. increased its holdings in MEDNAX by 32.1% in the 4th quarter. BBVA USA Bancshares Inc. now owns 14,033 shares of the company’s stock valued at $390,000 after purchasing an additional 3,409 shares in the last quarter. Nisa Investment Advisors LLC raised its position in MEDNAX by 84.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 53,920 shares of the company’s stock valued at $1,498,000 after purchasing an additional 24,700 shares during the period. Finally, Man Group plc raised its position in MEDNAX by 97.9% in the third quarter. Man Group plc now owns 431,790 shares of the company’s stock valued at $9,767,000 after purchasing an additional 213,629 shares during the period. Hedge funds and other institutional investors own 93.19% of the company’s stock.
Several equities research analysts have recently weighed in on the company. Credit Suisse Group decreased their target price on MEDNAX from $29.00 to $22.00 and set an “outperform” rating for the company in a research report on Thursday. ValuEngine lowered MEDNAX from a “sell” rating to a “strong sell” rating in a research report on Friday, March 20th. SunTrust Banks upped their price target on MEDNAX from $27.00 to $30.00 and gave the stock a “hold” rating in a report on Wednesday, December 18th. JPMorgan Chase & Co. lowered their price objective on shares of MEDNAX from $33.00 to $20.00 and set a “neutral” rating for the company in a research report on Monday, February 24th. Finally, Robert W. Baird lowered their price objective on shares of MEDNAX from $24.00 to $21.00 and set a “neutral” rating for the company in a research report on Tuesday, March 3rd. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and two have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $24.69.
MEDNAX (NYSE:MD) last posted its quarterly earnings data on Thursday, February 20th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $0.08. The company had revenue of $905.38 million for the quarter, compared to the consensus estimate of $900.85 million. MEDNAX had a positive return on equity of 12.22% and a negative net margin of 42.63%. MEDNAX’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.92 EPS. On average, equities analysts predict that MEDNAX Inc will post 2.79 earnings per share for the current fiscal year.
MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services.
Further Reading: Marijuana Stocks Investing Considerations
Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MEDNAX Inc (NYSE:MD).
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.